Enan­ta's NASH drug bare­ly meets main goal in mid-stage study

A pla­toon of drug de­vel­op­ers big and small has long been work­ing on com­bat­ing NASH, a fat­ty liv­er dis­ease that has rav­aged the de­vel­oped world. On Wednes­day, Enan­ta Phar­ma­ceu­ti­cals un­veiled da­ta from a short mid-stage study which sug­gest­ed its liv­er drug had — by a mi­nus­cule mar­gin — met the main goal in NASH pa­tients.

The drug, EDP-305, is a Far­ne­soid X Re­cep­tor (FXR) ag­o­nist, akin to In­ter­cept’s $ICPT obeti­cholic acid, which pro­duced mixed da­ta in a land­mark phase III study. FXR is a nu­clear re­cep­tor and a  cru­cial reg­u­la­tor of bile acid lev­els in the liv­er and small in­tes­tine.

In the 12-week AR­GON-1 tri­al, EDP-305 was test­ed against a place­bo. The main goal was to as­sess the change in ALT lev­els (when the liv­er is dam­aged, ALT lev­els are el­e­vat­ed) as well as safe­ty and tol­er­a­bil­i­ty.

EDP-305 con­ferred a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion of 28 units per liter (U/L) in ALT lev­els, ver­sus 15 U/L for the place­bo arm at week 12. How­ev­er, the p-val­ue just about made the cut at 0.049.

Key sec­ondary goals, in­clud­ing a change in liv­er fat con­tent and lipids, were al­so met, the com­pa­ny said.

De­spite the bare­ly-there main goal win, Enan­ta’s lead study in­ves­ti­ga­tor of­fered his vote of con­fi­dence on the ex­per­i­men­tal drug.

“Based on da­ta from AR­GON-1, EDP-305 clear­ly dis­plays en­hanced ef­fi­ca­cy over oth­er sec­ond-gen­er­a­tion FXR ag­o­nists cur­rent­ly in de­vel­op­ment,” said Vlad Ratz­iu, the prin­ci­pal in­ves­ti­ga­tor of the study, in a state­ment.

But Baird’s Bri­an Sko­r­ney wasn’t im­pressed. “Al­though there are some nu­mer­i­cal dif­fer­ences across the ma­jor pa­ra­me­ters used as a ba­sis of com­par­i­son, the mod­est dif­fer­ences are like­ly to be just noise,” he said.

“Fur­ther de­vel­op­ment of EDP-305 has ques­tion­able val­ue, in our view, as the like­ly out­come is that it winds up hav­ing a clin­i­cal pro­file that mir­rors OCA in NASH, which is al­most a decade ahead.”

Shares of the Wa­ter­town, Mass­a­chu­setts-based Enan­ta $EN­TA slipped more than 10% to $64 in Thurs­day pre­mar­ket trad­ing.

Jay Lu­ly Enan­ta

As for EDP-305’s safe­ty pro­file, pru­ri­tus (se­vere itch­ing) emerged as the pri­ma­ry is­sue in the Phase II tri­al — the side-ef­fect al­so caused pause in In­ter­cept’s tri­als.

The ma­jor­i­ty of ad­verse events seen in the EDP-305 arm were pru­ri­tus, GI-re­lat­ed symp­toms as well as headaches and dizzi­ness. The in­ci­dence of pru­ri­tus ap­peared dose-re­lat­ed, with 51% of the sub­jects in the 2.5 mg arm com­pared to less than 10% in the 1 mg arm — which con­tributed to dis­con­tin­u­a­tions of 20.8% in the high­er dose arm, and 1.8% in the low­er dose.

“This is the da­ta point that gives us the great­est con­cern as we be­lieve it is OCA’s biggest com­mer­cial li­a­bil­i­ty,” Sko­r­ney added.

“How­ev­er, EDP-305 ap­peared to cause pru­ri­tus at a high­er rate than OCA. OCA had a pru­ri­tis rate of 23% in FLINT vs. 47% of pa­tients in the high dose of AR­GON1. RE­GEN­ER­ATE had a 51% rate of pru­ri­tis for OCA but the place­bo rate was 19% vs. 4% and 6% for AR­GON1 and FLINT, re­spec­tive­ly,” he said.

The com­pa­ny is now plan­ning on ini­ti­at­ing a 72-week Phase IIb study — AR­GON-2 — in the first half of 2020, Enan­ta chief Jay Lu­ly said.

Non-al­co­holic steato­hep­ati­tis, or NASH, is char­ac­ter­ized by a buildup of ex­cess fat in the liv­er that in­duces chron­ic in­flam­ma­tion and even­tu­al­ly cul­mi­nates in scar­ring that can lead to cir­rho­sis, liv­er fail­ure, can­cer and death. Dubbed the silent dis­ease, it is hard to di­ag­nose in the ear­ly stages, mak­ing it dif­fi­cult to es­ti­mate its preva­lence, but stud­ies show that it af­flicts up to 12% of the adult pop­u­la­tion in de­vel­oped coun­tries. Al­though there are no ap­proved drugs for the dis­ease, the size of the NASH mar­ket is ex­pect­ed to cross $20 bil­lion by 2025.

While oth­er ma­jor NASH con­tenders — Gilead $GILD (fail in Phase III) and In­ter­cept $ICPT (mixed win in Phase III) — have dis­closed the top-line num­bers of their late-stage tri­als, Gen­fit $GN­FT is ex­pect­ed to come out with its Phase III in­ter­im re­sults by ear­ly 2020.

So­cial im­age: Shut­ter­stock

IDC: Life Sci­ences Firms Must Em­brace Dig­i­tal Trans­for­ma­tion Now

Pre-pandemic, the life sciences industry had settled into a pattern. The average drug took 12 years and $2.9 billion to bring to market, and it was an acceptable mode of operations, according to Nimita Limaye, Research Vice President for Life Sciences R&D Strategy and Technology at IDC.

COVID-19 changed that, and served as a proof-of-concept for how technology can truly help life sciences companies succeed and grow, Limaye said. She recently spoke about industry trends at Egnyte’s Life Sciences Summit 2022. You should watch the entire session, free and on-demand, but here’s a brief recap of why she’s urging life sciences companies to embrace digital transformation.

Tom Barnes, Orna Therapeutics CEO

UP­DAT­ED: 'We have failed to fail': Mer­ck gam­bles $250M cash on a next-gen ap­proach to mR­NA — af­ter punt­ing its big al­liance with Mod­er­na

Merck went in deep on its collaboration with Moderna on new mRNA programs, and dropped them all over time, including their RSV partnership. But after writing off what turned out as one of the most successful infectious disease players in the business, Merck is coming in this morning with a new preclinical alliance — this time embracing a biotech that hopes to eventually outdo the famously successful mRNA in a new run at vaccines and therapeutics.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Kate Haviland, Blueprint Medicines CEO

Blue­print met all its end­points in bid for ex­pand­ed Ay­vak­it la­bel — but stock trends low­er any­way

Blueprint Medicines announced this morning that the second part of its study on Ayvakit in non-advanced systemic mastocytosis (SM) — a rare disease in which a type of white blood cells known as mast cells builds up — met all endpoints, but the biopharma left key questions unanswered.

In 212 patients, with 141 in the treatment arm and 71 in the control arm, patients who got Ayvakit saw an average 15.6-point decrease in their symptom scores compared to a 9.2-point decrease in the placebo arm at 24 weeks. In an extension study, those on Ayvakit saw their symptom scores drop by 20.2 points by week 48.

Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Up­dat­ed: Hit by an­oth­er PhI­II flop, Sanofi culls breast can­cer drug — sound­ing alarm for the class

Sanofi is officially giving up on its oral SERD.

The French drugmaker put out word Wednesday morning that it will discontinue the global development program of amcenestrant, the selective estrogen receptor degrader once billed as a top late-stage prospect. Having already failed a Phase II monotherapy test earlier this year, a combo with the drug also missed the bar in a second trial for breast cancer, triggering the decision to drop the whole program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Bayer's first DTC ad campaign for chronic kidney disease drug Kerendia spells out its benefits

Bay­er aims to sim­pli­fy the com­plex­i­ties of CKD with an ABC-themed ad cam­paign

Do you know the ABCs of CKD in T2D? Bayer’s first ad campaign for Kerendia tackles the complexity of chronic kidney disease with a play on the acronym (CKD) and its connection to type 2 diabetes (T2D).

Kerendia was approved last year as the first and only non-steroidal mineralocorticoid receptor antagonist to treat CKD in people with type 2 diabetes.

In the TV commercial launched this week, A is for awareness, B is for belief and C is for cardiovascular, explained in the ad as awareness of the connection between type 2 and kidney disease, belief that something can be done about it, and cardiovascular events that may be reduced with treatment.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

James Mock, incoming CFO at Moderna

Mod­er­na taps new CFO from PerkinElmer af­ter for­mer one-day CFO oust­ed

When Moderna hired a new CFO last year,  it didn’t expect to see him gone after only one day. Today the biotech named his — likely much more vetted — replacement.

The mRNA company put out word early Wednesday that after the untimely departure of then brand-new CFO Jorge Gomez, it has now found a replacement in James Mock, the soon-to-be former CFO at diagnostics and analytics company PerkinElmer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Etleva Kadilli, director of UNICEF’s supply division

GSK lands first-ever UNICEF con­tract for malar­ia vac­cine worth $170M

GSK has landed a new first from UNICEF the first-ever contract for malaria vaccines, worth up to $170 million for 18 million vaccine doses distributed over the next three years.

The vaccine, known as Mosquirix or RTS,S, won WHO’s backing last October after a controversial start, but UNICEF said these doses will potentially save thousands of lives every year.

“We hope this is just the beginning,” Etleva Kadilli, director of UNICEF’s supply division, said. “Continued innovation is needed to develop new and next-generation vaccines to increase available supply, and enable a healthier vaccine market. This is a giant step forward in our collective efforts to save children’s lives and reduce the burden of malaria as part of wider malaria prevention and control programmes.”

Joe Jonas (Photo by Anthony Behar/Sipa USA)(Sipa via AP Images)

So­lo Jonas broth­er car­ries Merz's new tune in Botox ri­val cam­paign

As the lyrics of his band’s 2019 pop-rock single suggest, Joe Jonas is only human — and that means even he gets frown lines. The 33-year-old singer-songwriter is Merz’s newest celebrity brand partner for its Botox rival Xeomin, as medical aesthetics brands target a younger audience.

Merz kicked off its “Beauty on Your Terms” campaign on Tuesday, featuring the Jonas brother in a video ad for its double-filtered anti-wrinkle injection Xeomin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.

Marisol Peron, Genmab SVP of communications and corporate affairs

Gen­mab launch­es cor­po­rate cam­paign am­pli­fy­ing its ‘knock your socks off’ an­ti­bod­ies

Genmab often talks about its “knock-your-socks-off” antibodies — and now the term is getting its own logo and corporate campaign.

The teal and purple logo for the acronym KYSO — Genmab pronounces it “ky-so” — debuts on Wednesday and comes on the heels of Genmab’s newly announced 2030 vision. That aspiration aims to expand Genmab’s drug development beyond oncology to include other serious diseases, while also doubling down on its own drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.